NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/27/2026
Back to search
Official data from USPTO
AARVIK THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
AARVIK THERAPEUTICS
ST13
US500000090879874Class
42
Filing
90879874
Registration
8118566
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
57
Latest update
01/28/2026
Trademark type
Word
Nice classes
42
Filing date
08/12/2021
Registration date
01/27/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/27/2026
Last transaction
01/28/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2024-01-00
First use in commerce
2024-01-00
Drawing code
4
Owner type
03
Owner location
Hayward, CA
Examiner
BELL, MARLENE D
Law office
M90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Aarvik Therapeutics, Inc.
Aarvik Therapeutics, Inc.
Representatives
Christopher D. Olszyk, Jr. FOX ROTHSCHILD LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific research for medical purposes in the field of cancerinfectious and neurologic diseases and disorders; research and development services in the field of antibodies; Scientific and technological services and research relating theretoscientific researchanalysis and testing in the fields of mono-specific antibodiesbi-specificmulti-specific antibodies; antibody-drug conjugatesT cellNK cellMacrophage engaging antibodies; Antibody engineering; Custom design and engineering of antibodies; Research and development of pharmaceuticals for the treatment of cancerinfectious and neurologic diseases and disorders; Consulting services in the fields of biotechnologypharmaceutical research and development and genetic science; Research development and establishment of testing specifications and procedures in the field of cancer researchscientific research in the field of cancer diagnosis and treatment; Providing scientific research information in the field of cancer researchproviding scientific research information in the field of cancer diagnosis and treatment
Publications
History of USPTO decisions and trademark events.
57 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/27/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/02/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/02/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/27/2025
IUAF
USE AMENDMENT FILED
12/01/2025
EISU
TEAS STATEMENT OF USE RECEIVED
12/01/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/21/2025
EX5G
SOU EXTENSION 5 GRANTED
10/21/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/21/2025
EEXT
SOU TEAS EXTENSION RECEIVED
05/29/2025
EXT5
SOU EXTENSION 5 FILED
05/28/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/03/2025
EX4G
SOU EXTENSION 4 GRANTED
11/30/2024
EXT4
SOU EXTENSION 4 FILED
11/29/2024
EEXT
SOU TEAS EXTENSION RECEIVED
11/29/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/28/2024
EX3G
SOU EXTENSION 3 GRANTED
05/27/2024
EXT3
SOU EXTENSION 3 FILED
05/27/2024
EEXT
SOU TEAS EXTENSION RECEIVED
05/27/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/30/2023
EX2G
SOU EXTENSION 2 GRANTED
11/28/2023
EXT2
SOU EXTENSION 2 FILED
11/28/2023
EEXT
SOU TEAS EXTENSION RECEIVED
11/28/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/27/2023
EX1G
SOU EXTENSION 1 GRANTED
01/25/2023
EXT1
SOU EXTENSION 1 FILED
01/25/2023
EEXT
SOU TEAS EXTENSION RECEIVED
01/25/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/29/2022
NEWN
NEW NOA TO ISSUE
10/17/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/28/2022
IUCN
NOTICE OF ALLOWANCE CANCELLED
07/26/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/31/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/31/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/31/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/31/2022
PUBO
PUBLISHED FOR OPPOSITION
05/31/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/11/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/23/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
04/20/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/20/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
04/20/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/20/2022
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/13/2022
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
04/12/2022
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/31/2022
ALIE
ASSIGNED TO LIE
03/30/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/26/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/24/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/23/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/23/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/17/2022
GNRT
NON-FINAL ACTION E-MAILED
03/17/2022
CNRT
NON-FINAL ACTION WRITTEN
03/17/2022
DOCK
ASSIGNED TO EXAMINER
03/10/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/04/2021
NWAP
NEW APPLICATION ENTERED
08/16/2021
Continuous trademark protection
Get notified about every new filing that threatens AARVIK THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.